Abstract

Helicobacter pylori (H. pylori), an established risk factor for gastric cancer, is suggested to also play a role in the development of pancreatic cancer; however, the association remains inconclusive. We examined this association among Japanese men and women. H. pylori and atrophic gastritis (AG) status were determined serologically, using blood sample collected during health checkups. A total of 20,116 subjects enrolled in the Japan Public Health Center-based Prospective Study Cohort II with available data on H. pylori seropositivity (anti-H. pylori) and AG were followed until the end of 2010. Cox proportional hazards models were used to calculate the hazard ratios (HR) and 95% confidence intervals (CI), using the information from the baseline survey. During 320,470 person-years of follow-up, 119 cases of pancreatic cancer were identified. No statically significant increase or decrease in pancreatic cancer risk was observed for H. pylori and AG status, independently or in combination. In a multivariable-adjusted model, we observed a non-significant decrease in the risk among those who had AG but were anti-H. pylori seronegative (HR 0.57, 95% CI 0.31–1.03). In a stratified analysis, we observed a statistically significant increased risk of pancreatic cancer for AG+ (HR 3.64, 95% CI 1.37–9.66), and AG+/anti-H. pylori− or AG+/anti-H. pylori+ (HR 5.21, 95% CI 1.14–23.87) among current smokers. Non-smokers in all categories of AG and anti-H. pylori showed a non-statistical decrease in the risk. There was no statistically significant interaction between H. pylori infection, AG status, and smoking status. Our findings suggest H. pylori seropositivity and AG, individually or in combination, are not associated with the risk of pancreatic cancer in a general Japanese population. Among current smokers, pancreatic cancer risk increased with AG, regardless of H. pylori infection status.

Details

Title
Helicobacter pylori infection, atrophic gastritis, and risk of pancreatic cancer: A population-based cohort study in a large Japanese population: the JPHC Study
Author
Hirabayashi Mayo 1 ; Inoue Manami 2   VIAFID ORCID Logo  ; Sawada Norie 2 ; Saito Eiko 3 ; Abe, Sarah K 2 ; Hidaka Akihisa 2 ; Iwasaki Motoki 2 ; Yamaji Taiki 2 ; Shimazu Taichi 2   VIAFID ORCID Logo  ; Tsugane Shoichiro 2   VIAFID ORCID Logo 

1  The University of Tokyo, Department of Global Health Policy, Graduate School of Medicine, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
2  National Cancer Center, Epidemiology and Prevention Group, Center for Public Health Sciences, Chuo-ku, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385) 
3  The University of Tokyo, Department of Global Health Policy, Graduate School of Medicine, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); National Cancer Center, Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, Chuo-ku, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41598-019-42365-w
ProQuest document ID
2210006903
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.